產(chǎn)品編號 | BIO0991SM |
英文名稱 | Anti-IL-17 & TNF-alpha Reference Antibody (COVA322 Biosimilar) |
別 名 | IL-17 / IL-17A / CTLA-8 & TNF-alpha; COVA322 |
抗體來源 | |
克隆類型 | Monoclonal |
交叉反應 | Human |
產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 161.9kDa |
性 狀 | Lyophilized |
亞 型 | IgG-VHH |
純化方法 | Protein A |
緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
保存條件 | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 | |
產(chǎn)品圖片 |
Cova322 bound to HuTNF-a-his/CHO-K(0706-32-15) cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Cova322 bound to HuTNF-a-his/CHO-K(0706-32-15) cells, and the EC50 was 99.590 nM.
Cova322 bound to TNFSF2 / TNFα protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Cova322 bound TNFSF2 / TNFa, and the EC50 was 0.03458 nM.
Cova322 bound to CTLA-8 / IL-17a protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Cova322 bound human CTLA-8 / IL-17a Protein-His, and the EC50 was 0.03639 nM.
The purity of Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) is 98.28%, determined by SEC-HPLC.
Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
1、抗體溶解方法 | |
2、抗體修復方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關于肽鏈的設計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |